Quantinno Capital Management LP Takes Position in Zenas BioPharma, Inc. $ZBIO

Quantinno Capital Management LP acquired a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 21,126 shares of the company’s stock, valued at approximately $413,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBIO. Geode Capital Management LLC boosted its position in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter. Rhumbline Advisers raised its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares during the last quarter. Sei Investments Co. acquired a new stake in Zenas BioPharma during the 2nd quarter valued at approximately $118,000. Bank of America Corp DE lifted its stake in Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after acquiring an additional 3,412 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Zenas BioPharma by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after acquiring an additional 170,546 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ZBIO shares. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a report on Friday, August 14th. Weiss Ratings lowered shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.71.

Zenas BioPharma Price Performance

Shares of NASDAQ ZBIO opened at $32.29 on Friday. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -3.59 and a beta of -1.03. Zenas BioPharma, Inc. has a 12 month low of $13.50 and a 12 month high of $44.60. The firm’s 50 day simple moving average is $28.27 and its 200-day simple moving average is $23.78. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. Analysts expect that Zenas BioPharma, Inc. will post -5.81 EPS for the current year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.